Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Erweiterte Suche bearbeiten
Filter bei nächster Suche beibehalten
topic_facet:"Study Type: Interventional"
journalStr:"WHO International Clinical Trials Registry Platform"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=topic_facet%3A%22Study+Type%3A+Interventional%22&filter%5B%5D=journalStr%3A%22WHO+International+Clinical+Trials+Registry+Platform%22&join=AND&bool0%5B%5D=AND&lookfor0%5B%5D=ritonavir&type0%5B%5D=AllFields&op0%5B%5D=OR
/vufind/Search/Results?filter%5B%5D=topic_facet%3A%22Study+Type%3A+Interventional%22&filter%5B%5D=journalStr%3A%22WHO+International+Clinical+Trials+Registry+Platform%22&join=AND&bool0%5B%5D=AND&lookfor0%5B%5D=ritonavir&type0%5B%5D=AllFields&op0%5B%5D=OR
Search /vufind/Search2/Results?filter%5B%5D=topic_facet%3A%22Study+Type%3A+Interventional%22&filter%5B%5D=journalStr%3A%22WHO+International+Clinical+Trials+Registry+Platform%22&join=AND&bool0%5B%5D=AND&lookfor0%5B%5D=ritonavir&type0%5B%5D=AllFields&op0%5B%5D=OR
PubPharm (1.226)
1
Switch to MK-1439A from Ritonavir-boosted Protease Inhibitor regimen in HIV-1 infected subjects : A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs).SUBTITLE: Amendment to Include Switches From Additional Antiretroviral Regimens. - Switch to MK-1439A from PI, EVG- or NNRTI-based regimen for HIV-1 infection
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
2
Substitution current ARV therapy by BIKTARVY in hiv infected patients over 65 years old : Switch to Tenofovir Alafenamide (TAF), Emtricitabine (FTC), Bictegravir (BIC)(Biktarvy®) in HIV-1-infected patients over 65 years old at risk of polymedication - BILOLDER
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
3
Switch to MK-1439A from Ritonavir-boosted Protease Inhibitor regimen in HIV-1 infected subjects : A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs).SUBTITLE: Amendment to Include Switches From Additional Antiretroviral Regimens. - Switch to MK-1439A from PI, EVG- or NNRTI-based regimen for HIV-1 infection
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
4
Substitution current ARV therapy by BIKTARVY in hiv infected patients over 65 years old : Switch to Tenofovir Alafenamide (TAF), Emtricitabine (FTC), Bictegravir (BIC)(Biktarvy®) in HIV-1-infected patients over 65 years old at risk of polymedication - BILOLDER
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
5
A PHASE 3B, RANDOMISED, OPEN-LABEL STUDY OF THE ANTIVIRAL ACTIVITY AND SAFETY OF DOLUTEGRAVIR COMPARED TO LOPINAVIR/RITONAVIR BOTH ADMINISTERED WITH DUAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR THERAPY IN HIV-1 INFECTED ADULT SUBJECTS WITH TREATMENT FAILURE ON FIRST LINE THERAPY : A PHASE 3B, RANDOMISED, OPEN-LABEL STUDY OF THE ANTIVIRAL ACTIVITY AND SAFETY OF DOLUTEGRAVIR COMPARED TO LOPINAVIR/RITONAVIR BOTH ADMINISTERED WITH DUAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR THERAPY IN HIV-1 INFECTED ADULT SUBJECTS WITH TREATMENT FAILURE ON FIRST LINE THERAPY
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
6
A PHASE 3, RANDOMIZED, OPEN LABEL, CONTROLLED STUDY OF LOPINAVIR/RITONAVIR AND LAMIVUDINE VERSUS STANDARD THERAPY IN NAÏVE HIV-1 INFECTED SUBJECTS. : A PHASE 3, RANDOMIZED, OPEN LABEL, CONTROLLED STUDY OF LOPINAVIR/RITONAVIR AND LAMIVUDINE VERSUS STANDARD THERAPY IN NAÏVE HIV-1 INFECTED SUBJECTS.
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
7
A5290 RIFAMPIN-BASED TB TREATMENT VS. RIFABUTIN-BASED TB TREATMENT IN HIV : AA5290 Randomized, Phase 2b Study of a Double-Dose Lopinavir/Ritonavir-Based Antiretroviral Regimen with Rifampin-Based Tuberculosis Treatment versus a Standard-Dose Lopinavir/Ritonavir-Based Antiretroviral Regimen with Rifabutin-Based Tuberculosis Treatment with or without Raltegravir in HIV-1-Infected Persons Requiring Treatment for Active TB and HIV
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
8
A PROSPECTIVE SINGLE ARM, OPEN-LABEL, INTERNATIONAL, MULTICENTER STUDY TO EVALUATE THE SAFETY OF ATAZANAVIR (ATV) CAPSULE BOOSTED WITH RITONAVIR (RTV) WITH AN OPTIMIZED NRTI BACKGROUND THERAPY, IN HIV INFECTED, ANTIRETROVIRAL NAÏVE AND EXPERIENCED PEDIATRIC SUBJECTS GREATER THAN OR EQUAL TO 6 YEARS TO LESS THAN 18 YEARS. : A PROSPECTIVE SINGLE ARM, OPEN-LABEL, INTERNATIONAL, MULTICENTER STUDY TO EVALUATE THE SAFETY OF ATAZANAVIR (ATV) CAPSULE BOOSTED WITH RITONAVIR (RTV) WITH AN OPTIMIZED NRTI BACKGROUND THERAPY, IN HIV INFECTED, ANTIRETROVIRAL NAÏVE AND EXPERIENCED PEDIATRIC SUBJECTS GREATER THAN OR EQUAL TO 6 YEARS TO LESS THAN 18 YEARS.
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
9
A RANDOmZED, OPEN-LABEL STUDY OF THE ANTIVIRAL EFFICACV ANDSAFETY OF ATAZANAVIR, IN COMBINATION WITH RITONAVIR ORSAQUINAVIR, AND THE COMBINATION OF LOPINAVIR/RITONAVIR EACHWITH TENOFOVIR AND A NUCLEOSIDE IN SUBJECTS WHO HAVEEXPERIENCED VIROLOGIC FAILURE : A RANDOmZED, OPEN-LABEL STUDY OF THE ANTIVIRAL EFFICACV ANDSAFETY OF ATAZANAVIR, IN COMBINATION WITH RITONAVIR ORSAQUINAVIR, AND THE COMBINATION OF LOPINAVIR/RITONAVIR EACHWITH TENOFOVIR AND A NUCLEOSIDE IN SUBJECTS WHO HAVEEXPERIENCED VIROLOGIC FAILURE
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
10
Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV : STUDY RANDOMIZED OPEN ON THE EFFICACY AND SAFETY OF ATAZANAVIR IN COMBINATION WITH RITONAVIR OR SAQUINAVIR, AND THE COMBINATION OF LOPINAVIR / RITONAVIR, EACH ONE IN COMBINATION WITH TENOFOVIR AND A NUCLEOSID, IN PATIENTS WHO EXPERIENCED VIROLOGICAL FAILURE.
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
1
2
3
4
5
6
7
8
9
10
11
Nächster »
[123]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Alle gewählten Filter entfernen
Filter aufheben
Thema: Study Type: Interventional
Filter aufheben
Zeitschrift: WHO International Clinical Trials Registry Platform
Medienart
1.226
Aufsätze
1.226
E-Artikel
1.226
E-Ressourcen
Zeitschriftentitel
WHO International Clinical Trials Registry Plat...
Thema
1.226
610
Study Type: Interventional
886
Recruitment Status: Not yet recruiting
250
Phase: Phase 3
126
Recruitment Status: Authorised-recruitment may ...
120
Phase: Phase 2
116
Phase: Phase 4
82
Recruitment Status: Recruiting
74
Recruitment Status: Completed
48
Medical Condition: Chronic Hepatitis C Infectio...
20
Medical Condition: HIV-1 MedDRA version: 9.1Lev...
18
Medical Condition: Novel Coronavirus Pneumonia ...
18
Medical Condition: SARS-CoV-2 Infection MedDRA ...
18
Medical Condition: Treatment of HIV-1 infection
16
Medical Condition: Chronic Hepatitis C Infectio...
16
Medical Condition: Coronavirus Disease 2019 (CO...
16
Medical Condition: HIV
16
Medical Condition: HIV-1 infection
16
Medical Condition: The proposed indication for ...
14
Medical Condition: HIV-1 Infected Treatment Nai...
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
420
2020-
806
2010-2019
Erscheinungsjahr(e)
Von:
Bis:
Sprache
1.150
Englisch
42
Spanisch
24
Unbestimmt
8
Französisch
2
Deutsch
Alle anzeigen ...
weniger ...
Haven't found what you're looking for?
Wird geladen...